FX006 clinical trials
Also written FX006.
A product of Triamcinolone Acetonide; its studies count on that page too.
How each study uses FX006 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 3 Dec 1957 · ARISTOCORT · NDA 011161 (FDA, Drugs@FDA; as Triamcinolone)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 2
Pacira Pharmaceuticals, Inc (15) · The University of Texas Health Science Center, Houston (1) · Northwell Health (1)
Related medicines
As reviewed, each with the page that says it.
- A brand or code of Triamcinolone Acetonide
- One of Corticosteroids source
Studies
Open first, then newest update. How each study uses FX006 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff DiseaseTerminatedPhase 3Northwell HealthNCT04094298Written as FX006 Injection
- Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the HipCompletedPhase 2Pacira Pharmaceuticals, IncNCT04065074Written as FX006 32 mg
- Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or HipCompletedPhase 2Pacira Pharmaceuticals, IncNCT03382262Written as FX006 32 mg
- Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OACompletedPhase 2Pacira Pharmaceuticals, IncNCT03378076Written as FX006 32 mg
- Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the KneeCompletedPhase 2Pacira Pharmaceuticals, IncNCT02003365Written as FX006 10 mg
- Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the KneeCompletedPhase 2Pacira Pharmaceuticals, IncNCT02116972Written as FX006 32 mg
- Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the KneeCompletedPhase 3Pacira Pharmaceuticals, IncNCT03046446Written as FX006 32 mg
- Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the KneeCompletedPhase 2Pacira Pharmaceuticals, IncNCT02637323Written as FX006 32 mg
- Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the KneeCompletedPhase 3Pacira Pharmaceuticals, IncNCT02357459Written as FX006
- Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 DiabetesCompletedPhase 2Pacira Pharmaceuticals, IncNCT02762370Written as FX006 32 mg
- Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the KneeCompletedPhase 2Pacira Pharmaceuticals, IncNCT01487200Written as FX006 10 mg
- Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the KneeCompletedPhase 3Pacira Pharmaceuticals, IncNCT03529942Written as FX006 32 mg
- Study of FX006 in Patients With Osteoarthritis of the KneeCompletedPhase 2Pacira Pharmaceuticals, IncNCT01487161Written as FX006
- Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive CapsulitisTerminatedPhase 2Pacira Pharmaceuticals, IncNCT04160091Written as FX006
- Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip OsteoarthritisTerminatedPhase 3Pacira Pharmaceuticals, IncNCT03793010Written as FX006
- Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the KneeTerminatedPhase 2Pacira Pharmaceuticals, IncNCT02468583Written as FX006 32 mg
- Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric BursitisCompletedPhase 2The University of Texas Health Science Center, HoustonNCT04182672Written as FX006
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
- Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff DiseaseNov 4, 2026NCT04094298
Stopped1
- Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff DiseaseTerminatedNov 4, 2026NCT04094298
Codes
What other systems call FX006 · ClinicalTrials.gg INT001115
- MeSH (NLM) C000631825FX006One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000631825 | FX006 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.